-
Mashup Score: 0Fixed-Duration Regimen Safe, Effective for CLL | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. Patients with previously untreated chronic lymphocytic leukemia (CLL) who receive one-year fixed-duration treatment with venetoclax-obinutuzumab (Ven-Obi) experience sustained long-term survival, undetectable measurable residual disease (uMRD), and quality-of-life (QoL) benefits. Othman Al-Sawaf, MD, a hematologist at the University Hospital of Cologne in Germany, and colleagues published the six-year results of the randomized
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Treatment with teclistamab in patients with relapsed or refractory multiple myeloma (R/R MM) who had been previously treated with an anti-B-cell maturation antigen (BCMA) treatment resulted in statistically significant and clinically meaningful responses to the antibody. The overall response rate (ORR) in the clinical trial was 52.5%, and 30.0% of patients achieved a complete response (CR) or better. The median
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
In patients with R/R #MultipleMyeloma and prior #BCMA therapy, treatment with #teclistamab resulted in statistically significant and clinically meaningful responses, with a 52.5% ORR and a CR or better in 30% of patients: https://t.co/5ygrrSNVH2
-
-
Mashup Score: 3Prognostic Factors and Treatment Outcome in Mycosis Fungoides and Sezary Syndrome | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. A long-term retrospective study by Zhuo-Fan Xu, MD, of the Chinese Academy of Medical Science in Beijing, and colleagues has revealed new factors that predict prognosis and can help in treatment selection for patients with advanced mycosis fungoides (MF) and Sezary syndrome (SS). The results, published in Hematology, confirm that patients with MF/SS experience a wide range of survival and risk of progression. The authors thus
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Recent findings from researchers in China confirm that patients with advanced #MycosisFungoides and #SezarySyndrome experience a wide range of survival and progression risk, with recommendations for the use of disease-specific risk-stratification methods: https://t.co/sNfvAwk3pe
-
-
Mashup Score: 2ASH Clinical News: November 2024 From the Desk Of... - 2 month(s) ago
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, previews what’s to come in November. Highlights include a feature on managing substance use disorders in p…
Source: www.youtube.comCategories: General Medicine News, Oncologists1Tweet-
See what's to come next month! Below, @AaronGerds previews the November issue, which includes a feature on managing substance use disorders in patients with #hematologic diseases, the experiences of clinicians working in the midst of a #war, and more: https://t.co/3nUNFMbn5X
-
-
Mashup Score: 5More Study Needed to Increase Usage of Hydroxyurea in Infants with SCD | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. Rec ent data from the first randomized trial on hydroxyurea treatment for preventing silent cerebral infarctions (SCIs) in infants with sickle cell disease (SCD) add support to early initiation of treatment. The findings, published in the American Journal of Hematology, also underscore the need for larger trials in this population. 1 James F. Casella, MD, the Rainey Professor of Pediatric Hematology at Johns
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Recent data from HU Prevent, the first randomized trial on #hydroxyurea to prevent silent cerebral infarctions in infants with #SCD, add support to the early initiation of treatment, but low utilization rates remain a problem: https://t.co/qvFuBYEeOo
-
-
Mashup Score: 4Iron Deficiency Remains Unresolved Years After Diagnosis | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. The majority of patients with iron deficiency did not have resolution of their condition within three years, according to a statewide retrospective study of more than 13,000 Minnesota residents. Among the individuals who did eventually have normal iron stores, resolution of their iron deficiency took almost two years. These results w ere published in Blood Advances. 1 “We found that in a large cohort of patients
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet-
#IronDeficiency can remain unresolved for years after diagnosis, according to a statewide retrospective study of more than 13,000 Minnesota residents which showed that most patients did not have resolution of their condition within three years: https://t.co/pOCm5IkRiM
-
-
Mashup Score: 0Study in Southern Africa Increases Insight on Prevalence of MGUS | ASH Clinical News | American Society of Hematology - 2 month(s) ago
Katie Robinson is a medical writer based in New York. Contrary to current insight, the incidence of monoclonal gammopathy of undetermined significance (MGUS) was similar between et hnicities, according to a study that compared the epidemiology of MGUS in the southern African country of Eswatini to results of a previous study of a mainly white cohort in Minnesota’s Olmsted County the U.S. 1 The study was published in JNCI Cancer Spectrum. “We were a bit surprised to find the prevalence of conventional
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Contrary to current insight, the incidence of #MGUS was similar between ethnicities, according to a study comparing the epidemiology of MGUS in the southern African country of Eswatini to the results of a previous U.S. study of a mainly white cohort: https://t.co/YEBSJVllUM https://t.co/jiU9GT3r2F
-
-
Mashup Score: 0Future of First-in-Class Roxadustat for Lower-Risk MDS Remains Uncertain | ASH Clinical News | American Society of Hematology - 3 month(s) ago
Leah Lawrence is a freelance health writer and editor based in Delaware. The phase III MATTERHORN trial comparing roxadustat with placebo in patients with transfusion-dependent, lower-risk myelodysplastic syndromes (MDS) failed to meet its primary endpoint with no significant difference between study arms for eight-week transfusion independence. However, post-hoc analysis focusing on the subgroup of patients with MDS with higher transfusion burden demonstrated a significant superiority compared with
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Despite not meeting its primary endpoint, post-hoc analysis of the phase III MATTERHORN trial focusing on the subgroup of patients with #MDS with higher #transfusion burden demonstrated significant superiority of #roxadustat compared with placebo: https://t.co/9gm2n1EOTp
-
-
Mashup Score: 2Pediatric T-LBL But Not T-ALL Harbors TRB::NOTCH1 Fusions With Increased Relapse Risk | ASH Clinical News | American Society of Hematology - 3 month(s) ago
Katie Robinson is a medical writer based in New York. NOTCH1 gene fusions in the T-cell receptor ß (TRB) were identified in some children with T-cell lymphoblastic lymphoma (T-LBL) and were associated with increased relapse risk, according to a clinical trial published in Blood. In contrast, the study found that TRB::NOTCH1 fusions were absent in children with T-cell acute lymphoblastic leukemia (T-ALL), which has similar clinical, genetic, morphologic, and immunophenotypic properties to T-LBL. “The
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
NOTCH1 gene fusions in TRB were identified in some children with T-cell #lymphoblastic #lymphoma and found to be associated with increased relapse risk, while TRB::NOTCH1 fusions were absent in children with T-cell #AcuteLymphoblasticLeukemia: https://t.co/w7TTMvqNKM https://t.co/MRlxQL5zBD
-
-
Mashup Score: 2FDA Grants R/R CTCL Treatment Approval | ASH Clinical News | American Society of Hematology - 3 month(s) ago
The U.S. Food and Drug Administration (FDA) granted denileukin diftitox-cxdl approval for the treatment of relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. The treatment is a recombinant fusion protein that works by targeting the IL-2 receptor found on malignant T cells and regulatory T cells (Tregs). This is the medication’s first indication. Approval was granted based on the results of an open-label, single-arm, multicenter, phase III trial
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
The #FDA granted approval to denileukin diftitox-cxdl for the treatment of R/R cutaneous T-cell #lymphoma after at least one prior systemic therapy based on findings demonstrating an ORR of 36.2%, CR of 8.7%, and median time to response of 14.1 months: https://t.co/rikO7bX1tB
-
One-year fixed-duration treatment with #venetoclax and #obinutuzumab led to sustained long-term survival, undetectable measurable residual disease, and quality-of-life benefits for patients with previously untreated #ChronicLymphocyticLeukemia: https://t.co/hQvevvIwGZ